Suppression of Alzheimer's Disease-Related Phenotypes by Geranylgeranylacetone in Mice

Tatsuya Hoshino, Koichiro Suzuki, Takahide Matsushima, Naoki Yamakawa, Toshiharu Suzuki, Tohru Mizushima

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Amyloid-β peptide (Aβ) plays an important role in the pathogenesis of Alzheimer's disease (AD). Aβ is generated by the secretase-mediated proteolysis of β-amyloid precursor protein (APP), and cleared by enzyme-mediated degradation and phagocytosis. Transforming growth factor (TGF)-β1 stimulates this phagocytosis. We recently reported that the APP23 mouse model for AD showed fewer AD-related phenotypes when these animals were crossed with transgenic mice expressing heat shock protein (HSP) 70. We here examined the effect of geranylgeranylacetone, an inducer of HSP70 expression, on the AD-related phenotypes. Repeated oral administration of geranylgeranylacetone to APP23 mice for 9 months not only improved cognitive function but also decreased levels of Aβ, Aβ plaque deposition and synaptic loss. The treatment also up-regulated the expression of an Aβ-degrading enzyme and TGF-β1 but did not affect the maturation of APP and secretase activities. These outcomes were similar to those observed in APP23 mice genetically modified to overexpress HSP70. Although the repeated oral administration of geranylgeranylacetone did not increase the level of HSP70 in the brain, a single oral administration of geranylgeranylacetone significantly increased the level of HSP70 when Aβ was concomitantly injected directly into the hippocampus. Since geranylgeranylacetone has already been approved for use as an anti-ulcer drug and its safety in humans has been confirmed, we propose that this drug be considered as a candidate drug for the prevention of AD.

Original languageEnglish
Article numbere76306
JournalPLoS One
Volume8
Issue number10
DOIs
Publication statusPublished - 2013 Oct 1

Fingerprint

geranylgeranylacetone
Alzheimer disease
Alzheimer Disease
Phenotype
phenotype
amyloid
oral administration
mice
Oral Administration
transforming growth factors
Amyloid Precursor Protein Secretases
Transforming Growth Factors
phagocytosis
Phagocytosis
drugs
Anti-Ulcer Agents
Proteolysis
HSP70 Heat-Shock Proteins
Amyloid beta-Protein Precursor
Enzymes

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Hoshino, T., Suzuki, K., Matsushima, T., Yamakawa, N., Suzuki, T., & Mizushima, T. (2013). Suppression of Alzheimer's Disease-Related Phenotypes by Geranylgeranylacetone in Mice. PLoS One, 8(10), [e76306]. https://doi.org/10.1371/journal.pone.0076306

Suppression of Alzheimer's Disease-Related Phenotypes by Geranylgeranylacetone in Mice. / Hoshino, Tatsuya; Suzuki, Koichiro; Matsushima, Takahide; Yamakawa, Naoki; Suzuki, Toshiharu; Mizushima, Tohru.

In: PLoS One, Vol. 8, No. 10, e76306, 01.10.2013.

Research output: Contribution to journalArticle

Hoshino, T, Suzuki, K, Matsushima, T, Yamakawa, N, Suzuki, T & Mizushima, T 2013, 'Suppression of Alzheimer's Disease-Related Phenotypes by Geranylgeranylacetone in Mice', PLoS One, vol. 8, no. 10, e76306. https://doi.org/10.1371/journal.pone.0076306
Hoshino T, Suzuki K, Matsushima T, Yamakawa N, Suzuki T, Mizushima T. Suppression of Alzheimer's Disease-Related Phenotypes by Geranylgeranylacetone in Mice. PLoS One. 2013 Oct 1;8(10). e76306. https://doi.org/10.1371/journal.pone.0076306
Hoshino, Tatsuya ; Suzuki, Koichiro ; Matsushima, Takahide ; Yamakawa, Naoki ; Suzuki, Toshiharu ; Mizushima, Tohru. / Suppression of Alzheimer's Disease-Related Phenotypes by Geranylgeranylacetone in Mice. In: PLoS One. 2013 ; Vol. 8, No. 10.
@article{28c8e12da3754449ab810d8026b4769b,
title = "Suppression of Alzheimer's Disease-Related Phenotypes by Geranylgeranylacetone in Mice",
abstract = "Amyloid-β peptide (Aβ) plays an important role in the pathogenesis of Alzheimer's disease (AD). Aβ is generated by the secretase-mediated proteolysis of β-amyloid precursor protein (APP), and cleared by enzyme-mediated degradation and phagocytosis. Transforming growth factor (TGF)-β1 stimulates this phagocytosis. We recently reported that the APP23 mouse model for AD showed fewer AD-related phenotypes when these animals were crossed with transgenic mice expressing heat shock protein (HSP) 70. We here examined the effect of geranylgeranylacetone, an inducer of HSP70 expression, on the AD-related phenotypes. Repeated oral administration of geranylgeranylacetone to APP23 mice for 9 months not only improved cognitive function but also decreased levels of Aβ, Aβ plaque deposition and synaptic loss. The treatment also up-regulated the expression of an Aβ-degrading enzyme and TGF-β1 but did not affect the maturation of APP and secretase activities. These outcomes were similar to those observed in APP23 mice genetically modified to overexpress HSP70. Although the repeated oral administration of geranylgeranylacetone did not increase the level of HSP70 in the brain, a single oral administration of geranylgeranylacetone significantly increased the level of HSP70 when Aβ was concomitantly injected directly into the hippocampus. Since geranylgeranylacetone has already been approved for use as an anti-ulcer drug and its safety in humans has been confirmed, we propose that this drug be considered as a candidate drug for the prevention of AD.",
author = "Tatsuya Hoshino and Koichiro Suzuki and Takahide Matsushima and Naoki Yamakawa and Toshiharu Suzuki and Tohru Mizushima",
year = "2013",
month = "10",
day = "1",
doi = "10.1371/journal.pone.0076306",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Suppression of Alzheimer's Disease-Related Phenotypes by Geranylgeranylacetone in Mice

AU - Hoshino, Tatsuya

AU - Suzuki, Koichiro

AU - Matsushima, Takahide

AU - Yamakawa, Naoki

AU - Suzuki, Toshiharu

AU - Mizushima, Tohru

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Amyloid-β peptide (Aβ) plays an important role in the pathogenesis of Alzheimer's disease (AD). Aβ is generated by the secretase-mediated proteolysis of β-amyloid precursor protein (APP), and cleared by enzyme-mediated degradation and phagocytosis. Transforming growth factor (TGF)-β1 stimulates this phagocytosis. We recently reported that the APP23 mouse model for AD showed fewer AD-related phenotypes when these animals were crossed with transgenic mice expressing heat shock protein (HSP) 70. We here examined the effect of geranylgeranylacetone, an inducer of HSP70 expression, on the AD-related phenotypes. Repeated oral administration of geranylgeranylacetone to APP23 mice for 9 months not only improved cognitive function but also decreased levels of Aβ, Aβ plaque deposition and synaptic loss. The treatment also up-regulated the expression of an Aβ-degrading enzyme and TGF-β1 but did not affect the maturation of APP and secretase activities. These outcomes were similar to those observed in APP23 mice genetically modified to overexpress HSP70. Although the repeated oral administration of geranylgeranylacetone did not increase the level of HSP70 in the brain, a single oral administration of geranylgeranylacetone significantly increased the level of HSP70 when Aβ was concomitantly injected directly into the hippocampus. Since geranylgeranylacetone has already been approved for use as an anti-ulcer drug and its safety in humans has been confirmed, we propose that this drug be considered as a candidate drug for the prevention of AD.

AB - Amyloid-β peptide (Aβ) plays an important role in the pathogenesis of Alzheimer's disease (AD). Aβ is generated by the secretase-mediated proteolysis of β-amyloid precursor protein (APP), and cleared by enzyme-mediated degradation and phagocytosis. Transforming growth factor (TGF)-β1 stimulates this phagocytosis. We recently reported that the APP23 mouse model for AD showed fewer AD-related phenotypes when these animals were crossed with transgenic mice expressing heat shock protein (HSP) 70. We here examined the effect of geranylgeranylacetone, an inducer of HSP70 expression, on the AD-related phenotypes. Repeated oral administration of geranylgeranylacetone to APP23 mice for 9 months not only improved cognitive function but also decreased levels of Aβ, Aβ plaque deposition and synaptic loss. The treatment also up-regulated the expression of an Aβ-degrading enzyme and TGF-β1 but did not affect the maturation of APP and secretase activities. These outcomes were similar to those observed in APP23 mice genetically modified to overexpress HSP70. Although the repeated oral administration of geranylgeranylacetone did not increase the level of HSP70 in the brain, a single oral administration of geranylgeranylacetone significantly increased the level of HSP70 when Aβ was concomitantly injected directly into the hippocampus. Since geranylgeranylacetone has already been approved for use as an anti-ulcer drug and its safety in humans has been confirmed, we propose that this drug be considered as a candidate drug for the prevention of AD.

UR - http://www.scopus.com/inward/record.url?scp=84885037086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885037086&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0076306

DO - 10.1371/journal.pone.0076306

M3 - Article

C2 - 24098472

AN - SCOPUS:84885037086

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e76306

ER -